KIMMTRAK
(Tebentafusp)Phase 3Small molecule
KIMMTRAK is one of 96 small molecule programs targeting Uveal Melanoma. It is currently in Phase 3.
4
Indications
11
Total Trials
9
Active Trials
95
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
191 competitors in Melanoma
#DrugCompanyPhaseTrials
1Mekinist
NovartisPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Keytruda
Merck & Co.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Taxol
TevaPhase 3
Mektovi
PfizerPhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Lenvima
EisaiPhase 3
Intron a
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Uveal Melanoma5 trials
Show 2 more trials
Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT06246149·290 enrolled
Melanoma2 trials
Clear Cell Sarcoma1 trial
Cutaneous Melanoma1 trial
1 more indication
Regulatory
FDA Approval Timeline[4]
Jan 25, 2022
KIMMTRAK
BLA BLA761228
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tebentafusp. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- IImmunocore Ltd